This study highlights that GSK3β, as well as the HRR pathway, is a potential actionable target in FHIT-deficient lung cancer and provides the first candidate for FHIT-targeting synthetic lethal therapy for smokers with lung cancer. This evidence concerns the gene FHIT and lung carcinoma.